HKEX | Jotup

H World Announces Q4 and Full Year of 2023 Operating Results, Full Year RevPAR in China Recovered to 122% of the 2019 Level

Retrieved on:

星期三, 三月 20, 2024

Momentum, RevPAR, ADR, City, DH, OCC, HKEX, Tourism

Breaking down into each month, the RevPAR in October, November and December 2023 recovered to 120%, 117% and 123% of the 2019 levels, respectively.

Key Points:

Breaking down into each month, the RevPAR in October, November and December 2023 recovered to 120%, 117% and 123% of the 2019 levels, respectively.
For H World International (formerly known as DH), the ADR was EUR115, and the OCC for all H World International hotels in operation was 63.8%.
Commencing from February 2023, each monthly RevPAR consistently surpasses the 115% relative to the recovery of the 2019 level.
While the RevPAR growth in 2023 was primarily driven by ADR, H World also experienced continuous recovery in the occupancy rate.

NIO Inc. Files Its 2023 Annual Report on Form 20-F

Retrieved on:

星期二, 四月 9, 2024

Bank statement, Caobao Road station, Annual report, NIO, Security (finance), ADS, HKEX, Cryptocurrency

SHANGHAI, China, April 09, 2024 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the premium smart electric vehicle market, today filed its 2023 annual report on Form 20-F for the fiscal year ended December 31, 2023 with the Securities and Exchange Commission.

Key Points:

SHANGHAI, China, April 09, 2024 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the premium smart electric vehicle market, today filed its 2023 annual report on Form 20-F for the fiscal year ended December 31, 2023 with the Securities and Exchange Commission.
The annual report can be accessed on the Company’s investor relations website at https://ir.nio.com .
The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request.
Requests should be directed to Investor Relations Department, NIO Inc., Building 19, No.

Bilibili Inc. to Hold Annual General Meeting on June 28, 2024

Retrieved on:

星期二, 四月 9, 2024

Annual report, Exercise, AGM, Bank statement, Bilibili, HKEX

485 Zhengli Road, Yangpu District, Shanghai, People’s Republic of China on June 28, 2024 at 4:30 p.m. (Hong Kong time), to consider and vote on the resolutions set forth in the AGM Notice.

Key Points:

485 Zhengli Road, Yangpu District, Shanghai, People’s Republic of China on June 28, 2024 at 4:30 p.m. (Hong Kong time), to consider and vote on the resolutions set forth in the AGM Notice.
The AGM Circular, AGM Notice and form of proxy for the AGM are available on the Company’s investor relations website at http://ir.bilibili.com .
Bilibili has filed its annual report on Form 20-F, including its audited financial statements, for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission.
Bilibili’s Form 20-F can be accessed on the Company’s investor relations website at http://ir.bilibili.com and on the SEC’s website at http://www.sec.gov .

Bilibili Publishes 2023 Environmental, Social and Governance Report

Retrieved on:

星期二, 四月 9, 2024

PUE, Data analysis, ESG, Ethics, Social responsibility, Life, Carbon, Certification, Hobby, Social, Empowerment, Advertising, Love, HKEX, Intellectual property, Narrative of video games, Music

“With the mission to enrich the everyday life of young generations in China, Bilibili actively shoulders social responsibility,” said Mr. Rui Chen, chairman and chief executive officer of Bilibili.

Key Points:

“With the mission to enrich the everyday life of young generations in China, Bilibili actively shoulders social responsibility,” said Mr. Rui Chen, chairman and chief executive officer of Bilibili.
Highlights of Bilibili’s 2023 ESG achievements:
Bilibili fosters an ever-growing content ecosystem where all users can enjoy the fulfilling content they love.
In 2023, Bilibili:
Enabled over 3 million content creators to earn income on Bilibili, an increase of 30% from the previous year.
Engaged over 200 million users to study on Bilibili and over 2 million content creators to submit pan-knowledge content on Bilibili.

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

Retrieved on:

星期日, 四月 7, 2024

Renal carcinoma is the third most common malignancy of the urinary system globally, and RCC accounts for 80%~90% of all cases of renal carcinoma.

Key Points:

Renal carcinoma is the third most common malignancy of the urinary system globally, and RCC accounts for 80%~90% of all cases of renal carcinoma.
There were approximately 77,000 new cases of and 46,000 deaths due to renal carcinoma in China in 2022.
Distant metastasis occurred in about one-third of renal carcinoma patients at initial diagnosis, and in 20%-50% of localized patients after nephrectomy.
“The approval of toripalimab combined with axitinib addresses the gap in first-line immunotherapy for renal cancer in China.

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Retrieved on:

星期二, 四月 2, 2024

Toxicity, Radiation, Sintilimab, NMPA, Endometrial cancer, Disease, DCR, New Drug Application, Patient, NDA, Breakthrough therapy, Senior, Priority review, HKEX, Dor, IRC, Prognosis, PFS, Pharmaceutical industry

HONG KONG, SHANGHAI, China & FLORHAM PARK, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX:1801) today jointly announce that the New Drug Application (“NDA”) for the combination of fruquintinib and sintilimab for the treatment of patients with advanced endometrial cancer with pMMR1 or non-MSI-H2 tumors that have failed prior systemic therapy but are not candidates for curative surgery or radiation has been accepted and granted priority review by the China National Medical Products Administration (“NMPA”).

Key Points:

The NDA is supported by data from FRUSICA-1, the endometrial cancer registration cohort of a multi-center, open-label Phase II study investigating fruquintinib in combination with sintilimab in endometrial cancer patients who experienced disease recurrence, disease progression or intolerable toxicity with treatment on platinum-based doublet chemotherapy.
Data from FRUSICA-1 will be submitted for presentation at an upcoming medical conference.
“This is the first regulatory filing for the combination of fruquintinib and the immune checkpoint inhibitor sintilimab.
“Endometrial cancer remains one of the most common gynecological malignancies.

NIO Inc. Provides March and First Quarter 2024 Delivery Update

Retrieved on:

星期一, 四月 1, 2024

NIO, SUV, ES6, EC6, HKEX, ES8, Food delivery

NIO delivered 11,866 vehicles in March 2024, increasing by 14.3% year-over-year

Key Points:

NIO delivered 11,866 vehicles in March 2024, increasing by 14.3% year-over-year
Cumulative deliveries of NIO vehicles reached 479,647 as of March 31, 2024
SHANGHAI, China, April 01, 2024 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the premium smart electric vehicle market, today announced its March and first quarter 2024 delivery results.
NIO delivered 30,053 vehicles in the first quarter of 2024.
Beginning in March 2024, NIO started deliveries of its 2024 ES8, ES6, EC7, EC6 and ET5T.
The Company plans to start deliveries of the 2024 ES7, ET7 and ET5 soon in the second quarter of 2024.

XPENG Announces Vehicle Delivery Results for March and First Quarter 2024

Retrieved on:

星期一, 四月 1, 2024

EV, XPEV, XPENG, ADAS, G6, HKEX, Mobile phone

GUANGZHOU, China, April 01, 2024 (GLOBE NEWSWIRE) -- XPeng Inc. (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announced its vehicle delivery results for March and the first quarter of 2024.

Key Points:

GUANGZHOU, China, April 01, 2024 (GLOBE NEWSWIRE) -- XPeng Inc. (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announced its vehicle delivery results for March and the first quarter of 2024.
In March 2024, XPENG delivered 9,026 Smart EVs, representing a 99% increase over the prior month and 29% increase year-over-year.
The XPENG X9 maintained its position as the top-selling all-electric MPV in China, with 3,946 units delivered in March and nearly 8,000 units delivered since its launch.
Overall, XPENG delivered 21,821 Smart EVs in the first quarter of 2024, a 20% increase from last year.

Bilibili Inc. Announces Completion of the Repurchase Right Offer for 1.375% Convertible Senior Notes due 2026

Retrieved on:

星期五, 三月 29, 2024

Debt-to-GDP ratio, CUSIP, HKEX

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Bilibili Inc. (“Bilibili” or the “Company”) (NASDAQ: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced that it has completed its previously announced repurchase right offer relating to its 1.375% Convertible Senior Notes due 2026 (CUSIP No.

Key Points:

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Bilibili Inc. (“Bilibili” or the “Company”) (NASDAQ: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced that it has completed its previously announced repurchase right offer relating to its 1.375% Convertible Senior Notes due 2026 (CUSIP No.
090040AB2) (the “Notes”).
The repurchase right offer expired at 5:00 p.m., New York City time, on Thursday, March 28, 2024.
Based on information from Deutsche Bank Trust Company Americas as the paying agent for the Notes, US$429,331,000 aggregate principal amount of the Notes were validly surrendered and not withdrawn prior to the expiration of the repurchase right offer.

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Retrieved on:

星期四, 三月 28, 2024

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the supplemental New Drug Application (“sNDA”) for savolitinib, in adult patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) with mesenchymal epithelial transition factor (“MET”) exon 14 skipping alteration, has been accepted for review by the China National Medical Products Administration (NMPA). If approved, the new label indication for savolitinib will be expanded to include treatment-naïve patients in China.

Key Points:

Savolitinib was previously granted conditional approval in China for the treatment of patients with NSCLC with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy.
Savolitinib was launched and is marketed under the brand name ORPATHYS® by our partner, AstraZeneca for this patient population, representing the first selective MET inhibitor approved in China.
More than a third of the world’s lung cancer patients are in China and, among those with NSCLC globally, approximately 2-3% have tumors with MET exon 14 skipping alterations.
The data from this study provide confirmatory evidence for savolitinib as a targeted treatment option for treatment-naïve or previously treated patients with MET exon 14 skipping alteration NSCLC.